What is the Purpose of this Study?
Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) and CR -Assess long-term safety -Concomitant medications
Eligibility
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute : Marquis Keene, Saba Mukarram
More about this Clinical Trial
What is the full name of this clinical trial?
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from Study R3767-ONC-1613